The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Adipocytokines and Insulin Resistance
Open accessAbstract
Insulin resistance is defined as a failure of target organs to respond normally to the action of insulin. Insulin resistance causes incomplete suppression of hepatic glucose output and impaired insulin-mediated glucose uptake in the periphery (skeletal muscle and adipose), leading to increased insulin requirements. When increased insulin requirements are not matched by increased insulin levels, hyperglycemia develops. Insulin resistance is also known to be associated with other conditions such as central obesity, hypertension, and dyslipidemia, all risk factors for cardiovascular disease. The constellation of these metabolic abnormalities has been termed the metabolic syndrome. Obesity is a well-recognized risk factor for the development of insulin resistance and the metabolic syndrome. In addition to total amount of fat, distribution of adipose tissue is also important, with visceral depots contributing more to insulin resistance. The mechanisms by which accumulation and anatomic distribution of adipose tissue may be related to the development of insulin resistance are under intense investigation. Adipose tissue has traditionally been considered an energy storage organ, but over the last decade, a novel role of the adipose tissue as an endocrine organ has emerged (1). Adipose tissue is currently known to secrete a large number of factors with diverse functions. These factors include free fatty acids (FFA) with well described physiological and pathophysiological effects on glucose homeostasis (2), and proteins, termed adipocytokines, that act in an autocrine, paracrine, or endocrine fashion to control various metabolic functions (Table 1). Some of these adipocytokines have been implicated in the development of insulin resistance. They may act locally or distally to alter insulin sensitivity in insulin-targeted organs such as muscle and liver or may act through neuroendocrine, autonomic, or immune pathways. Here, we focus on certain adipocytokines and how they influence insulin sensitivity. We review potential insulin sensitizers such as leptin and adiponectin or insulin antagonists such as resistin, TNF-α, and IL-6. Proteins secreted by adipocytes that may act as signaling molecules Proteins secreted by adipocytes that may act as signaling molecules Since its discovery in 1994, leptin has assumed a pivotal role in energy homeostasis. Leptin is a 167-amino acid protein secreted by adipocytes in proportion to adipocyte tissue mass (3). Leptin circulates bound to a soluble form of its receptor and exerts its effects through binding to the leptin receptor (Ob-R), a member of the cytokine family of transmembrane receptors. There are five Ob-R isoforms; the best-characterized one is Ob-Rb, which activates the Jak-Stat signal transduction pathway. An important site of action of leptin is in the hypothalamus in which it regulates energy intake and expenditure and certain neuroendocrine axes. Some of the effects of leptin are mediated by direct actions on peripheral tissues. Insight into the physiology of leptin, including its relationship to insulin resistance, comes from the study of deficiency syndromes. Mice that are deficient in leptin (ob/ob) exhibit hyperphagia, obesity, hypercortisolemia, infertility, and diabetes (4). Exogenous leptin administration reverses these abnormalities (5). Of interest, in ob/ob mice, leptin reverses hyperglycemia and hyperinsulinemia at doses that do not decrease weight, suggesting an effect of leptin on insulin resistance that is independent of its effects on weight control (5). Leptin improves insulin resistance when injected in the cerebral ventricles, implying a mechanism mediated by the hypothalamus, possibly via activation of the adrenergic system. Leptin may also improve insulin sensitivity by directly acting on peripheral tissues such as skeletal muscle and liver (6, 7). Rare patients with a complete deficiency in leptin as a result of a mutation in the leptin gene have been described. These individuals are morbidly obese and display hormonal abnormalities such as hypogonadotropic hypogonadism and insulin resistance but not frank diabetes (8). Leptin replacement in these individuals had beneficial effects on energy intake, fat mass, hyperinsulinemia, and hyperlipidemia and pubertal development (9). Mutations in the human Ob-R resulting in a truncated receptor have also been described. These patients exhibited obesity and defects in hypothalamic endocrine axes but no diabetes (10). Individuals with complete leptin deficiency or resistance are rare. A small number of humans may have relatively low levels of leptin, suggesting a relative deficiency that may be treated with replacement. However, in humans, leptin levels correlate with the percentage of body fat, suggesting that most obese individuals become insensitive to endogenous leptin (3) and exogenous leptin administration is unlikely to have a major effect (11). The basis of leptin resistance in humans is unclear and ma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Effects of the obese Gene Product on Body Weight Regulation in ob / ob Mice
Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., & Collins, F. (1995) · Science · doi:10.1126/science.7624776 · Cited by 4,017
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis
Pittas, A. G., Lau, J., Hu, F. B., & Dawson-Hughes, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0298 · Cited by 2,001
Self-citationthe DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Morris, A. P., Voight, B. F., Teslovich, T. M., Ferreira, T., Segrè, A. V., Steinthorsdottir, V., Strawbridge, R. J., Khan, H., Grallert, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2383 · Cited by 1,912
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Metadata
- Authors
- Pittas, A. G., Joseph, N. A., & Greenberg, A. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02
- Volume
- 89
- Issue
- 2
- Pages
- 447-452
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1998009398
- Cited by
- 515
- References
- 81
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adipocytokines and Insulin Resistance. https://app.cochat.ai/papers/10.1210/jc.2003-031005
- The paper
- Pittas, A. G., Joseph, N. A., & Greenberg, A. S. (2004). Adipocytokines and Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-031005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.